Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

183.91USD
8:09pm BST
Change (% chg)

$1.14 (+0.62%)
Prev Close
$182.77
Open
$184.78
Day's High
$185.21
Day's Low
$182.15
Volume
524,063
Avg. Vol
1,131,642
52-wk High
$210.18
52-wk Low
$166.30

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 29.30 32.55
EPS (TTM): 11.00 -- --
ROI: 11.98 14.23 13.82
ROE: 26.43 15.46 15.24

BRIEF-Amgen Wins FDA Approval For Kanjinti Injection For Treatment Of Breast Cancer, Gastroesophageal Junction Adenocarcinoma - FDA

* AMGEN WINS FDA APPROVAL FOR KANJINTI INJECTION FOR TREATMENT OF BREAST CANCER, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - FDA WEBSITE

13 Jun 2019

Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

New York The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators. | Video

03 Jun 2019

US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

* Facebook, Amazon, Alphabet tumble on fears of regulatory risks

03 Jun 2019

US STOCKS-Wall Street falls as Facebook, Alphabet, Amazon drag

* Facebook, Amazon, Alphabet tumble on fears of regulatory risks

03 Jun 2019

US STOCKS-Wall Street tumbles as Facebook, Alphabet extend slide

* Facebook, Amazon, Alphabet tumble on fears of regulatory risks

03 Jun 2019

US STOCKS-Wall St edges higher, boosted by healthcare; Alphabet, Amazon pressure Nasdaq

* Dow up 0.34%, S&P gains 0.28%, Nasdaq down 0.40% (Adds quote, updates prices)

03 Jun 2019

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.

03 Jun 2019

UPDATE 1-Amgen drug shows high response rate in small lung and colon cancer trial

June 3 An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.

03 Jun 2019

Amgen drug shows high response rate in small lung and colon cancer trial

June 3 An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.

03 Jun 2019

Amgen to buy Copenhagen-based Nuevolution for $167 million

Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.

22 May 2019

Earnings vs. Estimates